Conference Proceedings

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

F Savira, BH Wang, AR Kompa, Z Ademi, A Owen, A Tonkin, S Zoungas, D Liew, E Zomer

EUROPEAN HEART JOURNAL | OXFORD UNIV PRESS | Published : 2020

Abstract

Abstract Background The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial demonstrated that dapagliflozin reduced heart failure hospitalisations and mortality in patients with established heart failure, regardless of diabetic status. Purpose To assess the cost-effectiveness of dapagliflozin in addition to standard care versus standard care alone in patients with chronic heart failure, from the perspective of the Australian public healthcare system. Methods A Markov model popu..

View full abstract